Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab + vedolizumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Combination therapy of adalimumab and vedolizumab for inflammatory bowel diseases. Adalimumab is a tumor necrosis factor (TNF) blocker that inhibits TNFα, while vedolizumab is an integrin receptor antagonist that targets α4β7 integrin on gut-homing T-lymphocytes. This dual biologic approach is used primarily for refractory Crohn's disease and ulcerative colitis.
- Brand names
- Entyvio + Humira
- Other names
- vedolizumab plus adalimumabdual targeted therapy with vedolizumab and adalimumab
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on adalimumab + vedolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab + vedolizumab.